This review will focus on the available evidence for PARP inhibitors combined separately with several agents, including anti-angiogenics, immune checkpoint inhibitors, phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), mammalian target of rapamycin (mTOR), WEE1, mitogen-activated protein kinase (MEK), and cyclin dependent kinase (CDK) 4/6 inhibitors, as well as the traditional chemotherapy in the ovarian cancer. This evidence concerns the gene PIK3CA and ovarian cancer.